Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Transcription Factor Mafa (269-353) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% thimerosal, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MAFA |
Gene ID: |
389692 |
Uniprot ID: |
MAFA_HUMAN |
Immunogen Region: |
269-353 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 269-353 of human MAFA (NP_963883.2). |
Immunogen Sequence: |
QSCRFKRVQQRHILESEKCQ LQSQVEQLKLEVGRLAKERD LYKEKYEKLAGRGGPGSAGG AGFPREPSPPQAGPGGAKGT ADFFL |
Tissue Specificity | Expressed in the islets of Langerhans (at protein level). |
Post Translational Modifications | Ubiquitinated, leading to its degradation by the proteasome. Phosphorylated at tyrosines. |
Function | Transcription factor that activates insulin gene expression. Acts synergistically with NEUROD1/BETA2 and PDX1. Binds the insulin enhancer C1/RIPE3b element. Binds to consensus TRE-type MARE 5'-TGCTGACTCAGCA-3' DNA sequence. |
Protein Name | Transcription Factor MafaPancreatic Beta-Cell-Specific Transcriptional ActivatorRipe3b1 FactorV-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A |
Database Links | Reactome: R-HSA-210745 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Transcription Factor Mafa antibodyAnti-Pancreatic Beta-Cell-Specific Transcriptional Activator antibodyAnti-Ripe3b1 Factor antibodyAnti-V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A antibodyAnti-MAFA antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance